カドニエモブと化学療法を併用した新しい治療法は,早期の胃がんに強い成果を示し,治療後は患者の半数が検出不能になつた. A new treatment combining cadonilimab and chemotherapy showed strong results in early-stage stomach cancer, with half of patients achieving no detectable cancer after treatment.

2025年のESMOアジア会議で発表された第2段階試験では,PD-1/CTLA-4双特異抗体であるカドニリマブと,切除可能な胃または消化管結節がんの新補助療法としてのSOX化学療法を組み合わせると,病理的な完全応答率が28. 6%となり,毎3週投与で50%に上昇することが判明した. A Phase II trial presented at the 2025 ESMO Asia Congress found that combining cadonilimab, a PD-1/CTLA-4 bispecific antibody, with SOX chemotherapy as neoadjuvant treatment for resectable gastric or gastroesophageal junction cancer resulted in a 28.6% pathological complete response rate, rising to 50% with every-three-week dosing. 主要病理学反応率は,Q3Wグループの71.4%,85.7%で,すべての患者がR0レセプションと著しい腫瘍の減少を遂げた. Major pathological response rates were 71.4% overall and 85.7% in the Q3W group, with all patients achieving R0 resection and significant tumor downstaging. 管理可能な安全性プロファイルを示した. The regimen showed a manageable safety profile. 進行中の第3相試験で,カドニリマブは中国で既に進行した胃がんの治療に承認されています. A Phase III trial is ongoing, and cadonilimab is already approved in China for advanced gastric cancer.